Conigen’s calcitonin receptor-like receptor (CALRL)- specific mouse mAb targeting the N-terminal domain (117aa) can potently bind the full length human CALRL expressed on live cells by flow cytometry and the N-terminus antigen by ELISA. 

CALRL (UniProt# Q16602), also known as CRLR and CLR, is a class B GPCR that plays a critical role in cardiovascular, lymphatic, and nervous system physiology. CALRL requires association with receptor activity-modifying proteins (RAMPs) to determine its ligand specificity and functional identity. When paired with RAMP1, CALRL functions as a receptor for calcitonin gene-related peptide (CGRP), a potent vasodilator involved in migraine pathophysiology. 

Clinically, CALRL is significant due to its involvement in diseases like migraine, cardiovascular disorders, and cancer. CGRP receptor antagonists targeting the CALRLRAMP1 complex have become effective therapies for migraine treatment. Additionally, dysregulation of adrenomedullin signaling through CALRL has been linked to tumor progression and poor prognosis in certain cancers. Ongoing research continues to explore CALRL as a therapeutic target, highlighting its importance in both normal physiology and disease. 

Conigen’s CALRL-specific live cell staining mouse mAb is a great addition to the research antibodies for flow cytometry and other in vitro binding assays, beyond the available antibody reagents for Western blot, immunohistochemistry, and immunofluorescence. It can be used for mechanism-of-action studies and drug discovery workflows, where CALRL expression can be elevated.